Valion Bio, Inc. Convertible Debt, Noncurrent
Valion Bio, Inc. (VBIO) had Convertible Debt, Noncurrent of $7.39 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent
us-gaap:ConvertibleDebtNoncurrent · last filed 2026-08-14
- 2026-06-30: Convertible Debt, Noncurrent $7.39M.
- 2026-03-31: Convertible Debt, Noncurrent $6.90M.
- 2025-12-31: Convertible Debt, Noncurrent $6.45M.
- 2024-12-31: Convertible Debt, Noncurrent $0.00.
| Period end | Convertible Debt, Noncurrent |
|---|---|
| 2026-06-30 | $7.39M 10-Q · filed 2026-08-14 |
| 2026-03-31 | $6.90M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $6.45M 10-Q · filed 2026-08-14 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |